Classification of hepcidin agonists
Hepcidin agonists . | Company . | Drug . | Target . | Clinical trials . | Reference . |
---|---|---|---|---|---|
Class 1: hepcidin mimetics | University of California, Los Angeles | MHs (PR65, PR73, M009, M012) | Ferroportin | Validated in preclinical studies | See articles cited in the review |
La Jolla Pharmaceutical Company | LJPC-401 (hepcidin formulation) | Ferroportin | Phase 1: no toxicity reported; expected hypoferremia observed | 45 | |
Protagonist Therapeutics | PTG-300 | Ferroportin | Phase 1: no serious adverse events reported; expected hypoferremia observed | 58 | |
Class 2: stimulators of hepcidin production | Ionis Pharmaceuticals | Tmprss6-ASO | Tmprss6 | Phase 1 ongoing | 59 |
Alnylam Pharmaceuticals | Tmprss6-siRNA | Tmprss6 | Validated in preclinical studies | See articles cited in the review | |
Class 3: ferroportin inhibitors | Vifor Pharma | VIT-2763 | Ferroportin | Phase 1 planned in 2018 | 60 |
Hepcidin agonists . | Company . | Drug . | Target . | Clinical trials . | Reference . |
---|---|---|---|---|---|
Class 1: hepcidin mimetics | University of California, Los Angeles | MHs (PR65, PR73, M009, M012) | Ferroportin | Validated in preclinical studies | See articles cited in the review |
La Jolla Pharmaceutical Company | LJPC-401 (hepcidin formulation) | Ferroportin | Phase 1: no toxicity reported; expected hypoferremia observed | 45 | |
Protagonist Therapeutics | PTG-300 | Ferroportin | Phase 1: no serious adverse events reported; expected hypoferremia observed | 58 | |
Class 2: stimulators of hepcidin production | Ionis Pharmaceuticals | Tmprss6-ASO | Tmprss6 | Phase 1 ongoing | 59 |
Alnylam Pharmaceuticals | Tmprss6-siRNA | Tmprss6 | Validated in preclinical studies | See articles cited in the review | |
Class 3: ferroportin inhibitors | Vifor Pharma | VIT-2763 | Ferroportin | Phase 1 planned in 2018 | 60 |
ASO, antisense oligonucleotide; siRNA, small-interfering RNA.